share_log

Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022

Benzinga Real-time News ·  May 5, 2022 08:18
  • LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects
  • A trend for stabilized or improved visual acuity was observed
  • Observed adverse events were anticipated based on the mechanism of LBS-008 action
  • STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment